跳至主要内容
临床试验/NCT01418053
NCT01418053已完成不适用

Randomised Controlled Study on the Effect of a Kneipp Hot Cataplasm With Caraway Oil in the Treatment of Irritable Bowel Syndrome

Universität Duisburg-Essen1 个研究点 分布在 1 个国家目标入组 48 人开始时间: 2011年8月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
48
试验地点
1
主要终点
Irritable Bowel Syndrome - Symptom Severity Score

研究概览

简要总结

The purpose of this study is to determine whether a daily use of a Kneipp hot cataplasm with caraway oil is effective in the treatment of abdominal pain and complaints caused by Irritable bowel syndrome.

详细描述

see above.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Irritable Bowel Syndrome according to Rom-III
  • Subtype Diarrhea or Alternating
  • discomfort or pain > 1 times a week
  • discomfort or pain > 4 on a Visual Analog Scale

排除标准

  • Inflammatory bowel diseases (test results necessary)
  • Lactose, Fructose Malabsorption (test results necessary)
  • Celiac Disease
  • Pregnancy or Breastfeeding
  • Colectomy or Hemicolectomy >50cm
  • Severe metabolic disorders, hormonal disorders, cardiac or respiratory failure, liver or renal diseases
  • severe depression, psychotic or psychiatric disorders, substance abuse
  • cancer within the last 5 years
  • allergy to caraway
  • acute inflammatory diseases

研究组 & 干预措施

Hot Cataplasm with Caraway Oil

Experimental

干预措施: caraway oil (Drug)

Hot Cataplasm with Olive oil

Active Comparator

干预措施: Olive oil (Drug)

Cold cataplasm with Olive oil

Active Comparator

干预措施: Olive oil (Drug)

结局指标

主要结局

Irritable Bowel Syndrome - Symptom Severity Score

时间窗: at T2 (Day 21)

IBS-SSS (Francis 1997)

次要结局

  • Frequency of abdominal discomfort/Pain(last week of treatment (days 14-21))
  • Intensity of abdominal discomfort/Pain(last week of treatment (days 14-21))
  • Quality of life(T2 (Day 21))
  • Quality of life - ibs specific(T2 (day 21))
  • Depression and Anxiety(T2 (day 21))
  • Global improvement(At day 7, 14 and 21)
  • h-BD2(T2 (day 21))
  • Adequate Relief Score(at day 7, 14, 21)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Jost Langhorst

Prof. Dr. med.

Universität Duisburg-Essen

研究点 (1)

Loading locations...

相似试验